The Sly Oncogene: FOXA1 Mutations in Prostate Cancer

Neel Shah; Myles Brown

doi:10.1016/j.ccell.2019.07.005

The Sly Oncogene: FOXA1 Mutations in Prostate Cancer

Cancer Cell. 2019 Aug 12;36(2):119-121. doi: 10.1016/j.ccell.2019.07.005.

Authors

Neel Shah¹, Myles Brown²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: myles_brown@dfci.harvard.edu.

PMID: 31408618
DOI: 10.1016/j.ccell.2019.07.005

Abstract

FOXA1 mutations occur frequently in prostate cancer and are associated with a worse clinical outcome. However, the mechanism by which these mutations act was until now largely unknown. Two recent publications clearly demonstrate that FOXA1 acts as an oncogene in prostate cancer and delineate the phenotypic effects of distinct classes of FOXA1 alterations.

Publication types

Comment

MeSH terms

Cell Line, Tumor
Gene Expression Regulation, Neoplastic*
Hepatocyte Nuclear Factor 3-alpha
Humans
Male
Mutation
Phenotype
Prostatic Neoplasms / genetics*

Substances

FOXA1 protein, human
Hepatocyte Nuclear Factor 3-alpha